

Selected Protocols for the Treatment of Hematologic Malignancies

Treatment Group	ID Number	Phase	Study Name	Principal Investigator
Lymphoma	08-063	Pilot	A Pilot Study of Gleevec (Imatinib Mesylate) in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma*	Eric Jacobsen, MD 617-632-6633
Lymphoma	06-275	I	A Phase I Trial of Vaccination with Lethally Irradiated Lymphoma Cells Admixed with GMCSF Secreting K562 Cells for the Treatment of Follicular Lymphoma	Eric Jacobsen, MD 617-632-6633
Lymphoma	08-019	IA/II	A Phase IA/II, Multicenter, Open-Label Study of HCD122 Administered Intravenously Once Weekly for Four Weeks in Adult Patients with Advanced Non-Hodgkin's or Hodgkin's Lymphoma who have Progressed after at Least Two Prior Therapies*	Arnold Freedman, MD 617-632-3441
Lymphoma	08-164	I/II	A Phase I/II Open-Label Study of Pralatrexate and Gemcitabine with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Lymphoproliferative Malignancies	Eric Jacobsen, MD 617-632-6633
Lymphoma	08-066	II	A Phase II Trial of Bortezomib + Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma*	Ann S. LaCasce, MD 617-632-5959
Lymphoma	08-264	II	A Phase II Study of Oral Panobinostat in Adult Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma after Failure of High-Dose Chemotherapy with Autologous Stem Cell Transfusion and a Gemcitabine- or Vinorelbine- or Vinblastine-Containing Treatment Regimen	David C. Fisher, MD 617-632-3039
Lymphoma	06-059	III	A Phase III Clinical Study to Investigate the Prevention of Relapse in Lymphoma using Daily Enzastaurin	Ann S. LaCasce, MD 617-632-5959
Leukemia	08-286	I	A Phase I Study of the HSP90 Inhibitor, STA-9090, Administered Twice-Weekly in Patients With Hematologic Malignancies	Daniel DeAngelo, MD, PhD 617-632-2645
Leukemia–AML, MDS	08-269	I	A Phase I Trial of Escalating Dose of RAD001 in Combination with PKC412 in Patients with Relapsed, Refractory or Poor Prognosis AML or MDS*	Richard M. Stone, MD 617-632-2214
Leukemia – ALL	07-177	I/II	A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TDT-Positive Leukemia*	Daniel DeAngelo, MD, PhD 617-632-2645
Leukemia – AML	08-051	II	A Phase II Open-Label, Multicenter Clinical Study of the Safety and Efficacy of SNS 595 Injection in Patients >60 Years of Age with Previously Untreated Acute Myeloid Leukemia*	Richard M. Stone, MD 617-632-2214
Leukemia – AML	08-112	III	A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients <60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia*	Richard M. Stone, MD 617-632-2214
Multiple Myeloma	08-031	I	An Open-Label Phase I Study of the Safety and Efficacy of GCS-100 Alone and in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma	Robert Schlossman, MD 617-632-5126

* Protocol also available at Massachusetts General Hospital Cancer Center

Treatment Group	ID Number	Phase	Study Name	Principal Investigator
Multiple Myeloma	07-353	I	A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma	Paul Richardson, MD 617-632-2104
Multiple Myeloma	07-254	I	A Phase I Study of Enzastaurin plus Bortezomib Therapy in the Treatment of Relapsed or Refractory Multiple Myeloma	Irene M. Ghobrial, MD 617-632-4198
Multiple Myeloma	07-313	I	A Phase IB, Multicenter, Open-Label, Dose Escalation Study of Oral LBH589 and IV Bortezomib in Patients with Multiple Myeloma	Kenneth Anderson, MD 617-632-2144
Multiple Myeloma	07-237	I	A Phase I Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of GRN163L in Patients with Refractory or Relapsed Multiple Myeloma*	Nikhil Munshi, MD 617-632-5607
Multiple Myeloma	07-395	I/II	A Phase I/II Multicenter, Randomized, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of CC-4047 Alone and in Combination with Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma who have Received Prior Treatment that Includes Lenalidomide and Bortezomib*	Paul Richardson, MD 617-632-2104
Multiple Myeloma	08-141	I/II	A Multi-Institutional Phase I/II Study of Revlimid (Lenalidomide), Velcade (Bortezomib), Dexamethasone, and Doxil (RVDD) Combination Therapy for Patients*	Robert L. Schlossman, MD 617-632-5126
Transplant	08-160	I	Vaccination with Lethally Irradiated Autologous Myeloblasts Admixed with GMCSF Secreting K562 Cells (GM-K562) in Patients with Advanced MDS or AML after Allogeneic Hematopoietic Stem Cell Transplant	Vincent Ho, MD 617-632-5938
Transplant	07-057	I	An Open-Label Phase I Trial of Alemtumab (Campath 1-H) Therapy for Refractory Chronic Graft-Versus-Host Disease	Corey Cutler, MD, MPH, FRCPC 617-632-5946
Transplant	07-083	I	A Phase I Study of Ultra-Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft-Versus-Host Disease	John Koreth, MBBS, D.Phil 617-632-2949
Transplant	06-196	I/II	Reduced Intensity Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia followed by Vaccination with Lethally Irradiated Autologous Tumor Cells Admixed With GMCSF Secreting K562 Cells	Catherine Wu, MD 617-632-5943
Transplant	06-158	I/II	Ludarabine-Based Conditioning for Allogeneic Marrow Transplantation from HLA-Compatible Unrelated Donors in Severe Aplastic Anemia	Joseph H. Antin, MD 617-632-2525
Transplant	07-413	Observational	A Prospective Observational Study of Iron Overload in Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Myeloablative Allogeneic Stem Cell Transplantation	Philippe Armand MD, PhD 617-632-2305

Dana-Farber/Brigham and Women's Cancer Center and Massachusetts General Hospital Cancer Center collaborate on clinical trials, education, and quality of care improvement. Clinical trials are conducted through the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center.

If you are interested or would like more information about the clinical trials listed, please contact the principal investigator. For a broader listing of treatment protocols, visit our website at www.dfbwcc.org/clinicaltrials.